Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy

Launched by THE NETHERLANDS CANCER INSTITUTE · Feb 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with colorectal cancer that has spread to the liver and cannot be surgically removed. The trial is comparing two treatment methods: one that combines a specialized pump therapy (Hepatic Arterial Infusion Pump therapy) with standard chemotherapy, and another that uses only the standard chemotherapy. The main goal is to find out if the combination therapy helps patients live longer compared to just using standard chemotherapy.

To participate in this trial, patients should be at least 18 years old, have been recently diagnosed with colorectal cancer that has spread to the liver, and not have had any previous chemotherapy treatments. They should also have a primary tumor that can be surgically removed and meet specific health criteria. If eligible, participants will undergo surgical procedures to place the pump and receive treatments while being monitored for their health and quality of life. The trial is currently recruiting participants of all genders, and it is important for interested patients to discuss their options with their doctor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years.
• • Histologically confirmed colorectal adenocarcinoma.
• • Unresectable synchronous CRLM according to a National Liver Panel (CT-scan obtained ≤ 4 weeks prior to registration).
• • No extrahepatic metastases. Patients with small (≤ 10 mm) extrahepatic lesions that are not clearly suspicious of metastases are eligible.
• • No previous systemic therapy for colorectal cancer.
• • Positioning of a catheter for HAIP chemotherapy is technically feasible based on imaging. The default site for the catheter insertion is the gastroduodenal artery (GDA). Accessory or aberrant hepatic arteries are no contra-indication for catheter implantation. The GDA should have at least one branch to the liver. Accessory or aberrant hepatic arteries should be ligated to allow for cross perfusion to the entire liver through intrahepatic shunts. Patients with celiac trunk stenosis are not eligible. Patients with both a replaced right and replaced left hepatic artery are not eligible.
• • ECOG performance status 0 or 1.
• • Life expectancy of at least 12 weeks.
• • Known mutation status of RAS and BRAFV600E.
• • Primary tumour in situ and resectable without neoadjuvant therapy.
• • Patient is eligible for surgery.
• • Patient is eligible for doublet chemotherapy.
• • Laboratory requirements: i.e. adequate bone marrow, liver and renal function (obtained within 15 days prior to registration).
• • Hb ≥ 5.5 mmol/L
• • absolute neutrophil count (ANC) ≥1.5 x 109/L
• • platelets ≥100 x 109/L
• • total bilirubin ≤ 1.5 times the upper limit of normal (ULN)
• • ASAT/AST ≤ 5 x ULN
• • ALAT/ALT ≤ 5 x ULN
• • alkaline phosphatase ≤ 5 x ULN
• • Serum creatinine ≤ 1.5 x upper limit of normal or a MDRD (eGFR) ≥ 45 ml/min;
• • Prothrombin time or INR \< 1.5 x ULN, unless coumarin derivates are used. All patients using coumarin derivates will be treated with LMWH or DOAC instead.
• • Before registration, written informed consent must be given and signed according to ICH/GCP, and national/local regulations.
• Exclusion Criteria:
• • Prior hepatic radiation, resection, or ablation.
• • Any malignancy, comorbidity or condition that interferes with the planned study treatment or the prognosis of CRLM, determined by the treating physician.
• • History of prior malignancy except for the following: (a) malignancy treated with curative intent and with no evidence of active disease present within 3 years prior to inclusion, (b) curatively treated malignancies felt to be at low risk for recurrence by treating physician and MDT, (c) adequately controlled nonmelanomatous skin cancer, (d) adequately treated carcinoma in situ without current evidence of disease.
• • Obstructive primary tumour requiring emergency surgery, primary tumour necessitating a multivisceral resection/abdominoperineal resection or a rectal tumour requiring preoperative short-course radiotherapy or chemoradiotherapy for local tumour control.
• • MMR deficiency.
• • DPD-deficiency.
• • Pregnant or lactating women.
• • Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
• • Organ allografts requiring immunosuppressive therapy.
• • Serious non-healing wound, ulcer, or bone fracture.
• • Chronic treatment with corticosteroids (dose of ≥ 10 mg/day methylprednisolone equivalent excluding inhaled steroids).
• • Known serious infections (uncontrolled or requiring treatment).
• • History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP-SYST or standard systemic therapy.
• • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
• • Underlying liver disease including liver fibrosis and cirrhosis